Related Experiment Video
Updated: Oct 30, 2025
08:16
Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
Published on: March 4, 2014
32.7K
Progressive supranuclear palsy: diagnosis and management.
James B Rowe1,2, Negin Holland3,4, Timothy Rittman3,4
1Department of Clinical Neurosciences, University of Cambridge, Cambridge, Cambridgeshire, UK james.rowe@mrc-cbu.cam.ac.uk.
Practical Neurology
|July 3, 2021
Summary
Proactive management of progressive supranuclear palsy (PSP) offers effective and rewarding patient care. A multidisciplinary approach addresses symptoms, risks, and the complexities of chronic neurological illness.
Area of Science:
- Neurology
- Geriatrics
- Palliative Care
Background:
- Progressive supranuclear palsy (PSP) presents significant management challenges for patients and families.
- Effective treatment requires a comprehensive understanding of the patient's medical, social, and legal context.
Purpose of the Study:
- To share experiences in the proactive management of PSP.
- To outline strategies for ameliorating symptoms, reducing risks, and guiding patients through chronic illness.
Main Methods:
- Review of clinical experience in managing PSP.
- Summary of diagnostic challenges, including differentiating PSP mimics.
- Discussion of pharmacological and non-pharmacological treatment strategies.
Main Results:
- Early diagnosis of PSP can be challenging.
- A range of treatments exist to manage common and difficult PSP symptoms.
- Patient-centered care within a multidisciplinary team is crucial.
Conclusions:
- Proactive and patient-centered management improves outcomes for individuals with PSP.
- Multidisciplinary team involvement is essential for holistic care.
- Addressing the multifaceted needs of PSP patients enhances quality of life.
Related Concept Videos
01:15Parkinson's Disease: Overview
1.0K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.0K
01:24Parkinson's Disease: Treatment
585
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
585
01:20Myasthenia Gravis: Overview and Treatment
2.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.2K
01:22Alzheimer's Disease: Treatment
437
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
437
01:26Psychosis: Goals of Pharmacotherapy
284
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
284
01:15Myasthenia Gravis: Diagnostic Tests
1.6K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.6K